Efficacy News and Research

RSS

Thrombogenics issues business update and half year results

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, is today issuing a business update and its half year results for the six month period ending 30 June, 2009.

28 Aug 2009

Milestone reached in Biotie Wyeth collaboration for the development of PDE10 inhibitors for schizophrenia

Biotie announced today that it has reached a milestone in its collaboration with Wyeth for the development of PDE10 (phosphodiesterase 10) inhibitors for schizophrenia, triggering a USD 1.0 million milestone payment to Biotie.

28 Aug 2009

NAT gains importance as traditional testing methods become inadequate

An expanding population of bacterial strains that are drug resistant, including methicillin-resistant Staphylococcus aureus (MRSA), will be the most important justification for nucleic acid-based tests (NAT).

28 Aug 2009

Opinion piece outlines new model for foreign aid

President Obama's "comments on foreign aid [in Ghana] make it all the more surprising that the only real change in our foreign assistance programs under his administration so far is in indicated spending" - Carol Adelman, director of the Center for Global Prosperity at the Hudson Institute, and Nicholas Eberstadt, a political economy scholar at the American Enterprise Institute - write in a Weekly Standard opinion piece.

28 Aug 2009

Elorac offers Zithranol-RR for treating plaque psoriasis

Now patients with mild to moderate plaque psoriasis have a new topical treatment option available by prescription. Zithranol™-RR (anthralin rapid release microcrystalline encapsulated cream, 1.2%), is an innovative topical therapy for plaque psoriasis according to Elorac, Inc., a privately held emerging dermatology company. Zithranol™-RR provides an advanced delivery system for anthralin achieving long remission times with no long-term side effects in a steroid-free, silky cream.

28 Aug 2009

Infectious Disease Research Institute commences clinical trial of its leishmaniasis vaccine in Sudan

IDRI (Infectious Disease Research Institute) announced today the start of a clinical trial in Sudan to test its leishmaniasis vaccine candidate for the treatment of post kala-azar dermal leishmaniasis (PKDL), a complication of visceral leishmaniasis (VL) which is observed in 50% of patients treated for VL in the country, predominantly affecting children.

28 Aug 2009

NIMH grants Xhale $1.7 million to develop the SMART medication adherence system for HIV/AIDS therapies

Xhale, Inc. has been awarded a $1.7 million Small Business Innovation Research (SBIR) Phase II grant by the NIH National Institute of Mental Health (NIMH) to continue the development of SMART (Self Monitoring and Reporting Therapeutics), a breath-based medication adherence system for HIV/AIDS therapies.

28 Aug 2009

Medical journal article highlights the challenges faced by healthcare providers for treating patients with non-healing wounds

Cardium Therapeutics today reported that a recent medical journal article highlights the challenges facing healthcare providers with respect to finding optimal treatments for patients with non-healing wounds.

28 Aug 2009

E-18 files for an international patent for its revolutionary self-sheathing medical safety syringe technology

E-18 Corp. (OTCBB:ETEN) today announced that its wholly owned subsidiary SquareOne Medical, Inc., doing business as Protectus Medical Devices ("Protectus Medical Devices"), completed an international patent filing for its revolutionary self-sheathing medical safety syringe technology, opening substantial opportunities abroad.

27 Aug 2009

Sunquest Information Systems to co-develop laboratory information system with MGH, Partners HealthCare System

Sunquest Information Systems, Inc., a market leader in laboratory and diagnostic information systems, the Massachusetts General Hospital (MGH), an innovator in medical care, research and teaching, and Partners HealthCare System, an integrated health care delivery system with a tradition of IT excellence, today announced a collaborative agreement to jointly develop the next generation anatomic and clinical pathology based laboratory information system.

27 Aug 2009

FDA approves clinical study of ATS 3f(R) Aortic Bioprosthesis with the younger aortic valve replacement population

ATS Medical, Inc. manufacturer and marketer of state-of-the-art cardiac surgery products and services, announced today that the FDA has approved a landmark clinical study in which cardiac surgeons will implant the ATS 3f(R) Aortic Bioprosthesis in a younger aortic valve replacement patient population that has not been previously studied in a controlled and scientific manner.

27 Aug 2009

Clinical data added to ORENCIA labeling help treat patients with rheumatoid arthritis

Bristol-Myers Squibb Company announced today that clinical data added to the labeling for ORENCIA (abatacept) support use of ORENCIA for patients with moderate to severe rheumatoid arthritis of less than or equal to two years duration.

27 Aug 2009

Stemedica unveils two of its latest scientific discoveries at the 2009 World Stem Cell Summit

Stemedica Cell Technologies , Inc., ("Stemedica"), a world leader in stem cell research and manufacturing (a licensed manufacturer of clinical grade biological products as licensed by the State of California Food and Drug Branch) continues to advance the stem cell industry with the presentation of two of its latest scientific discoveries at the 2009 World Stem Cell Summit.

27 Aug 2009

BMSN and ENTB collaborate with Therinjectto to develop a new immuno-therapeutic cancer vaccine

Bio-Matrix Scientific Group, Inc. and Its majority owned subsidiary Entest BioMedical Inc. announced today they have finalized a definitive agreement with Therinject LLC for the development of a new immuno-therapeutic cancer vaccine. Therinject LLC is engaged in the development of cancer treatments utilizing immunology based approaches.

27 Aug 2009

QRxPharma completes its pilot evaluation study investigating the efficacy of MoxDuo capsules

QRxPharma Limited and announced today successful completion of its pilot study to evaluate the analgesic efficacy and safety profile of MoxDuo(TM) IR (immediate release) capsules in patients with moderate to severe pain following total knee replacement surgery.

27 Aug 2009

Study reveals effectiveness of BioElectronics' ActiPatch therapy device for treating heel and foot pain

BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced the completion of an important clinical study on heel and foot pain, which was led by David Genecov, M.D. FACS FAAP.

27 Aug 2009

Link between collagen deficiency and osteoarthritis found in mice

Osteoarthritis (OA) and degenerative disc disease (DDD) are common, chronic musculoskeletal disorders. Both diseases cause joint pain, loss of function, and decreased quality of life for the more than 27 million OA and 59 million DDD suffers in the US. According to a 2003 Medical Expenditure Panel Survey, arthritis such as OA costs the U.S. economy nearly $128 billion per year in medical care and indirect expenses including lost wages and productivity.

27 Aug 2009

FDA releases consumer health information updates

The U.S. Food and Drug Administration today released its latest listing of consumer health information updates. All articles can be accessed from the agency's Web page for consumers. You can sign-up for e-mail notices of new consumer updates on an immediate, weekly, or monthly basis. A Consumer Update RSS feed is also available.

27 Aug 2009

Collagen deficiency in mice causes premature development of osteoarthritis and degenerative disc disease

27 Aug 2009

BioAlliance Pharma's LIP phase III pivotal study provides positive preliminary results

BioAlliance Pharma SA (Paris:BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, is pleased today to announce positive preliminary results in its LIP phase III pivotal study (Lauriad® Immunocompetent Patients Study ). This multicenter randomized, double-blind, placebo controlled study compared the efficacy and safety of a single dose acyclovir Lauriad® 50mg Mucoadhesive Buccal Tablet (MBT) versus matching placebo in patients suffering from recurrent oro-facial herpes.

27 Aug 2009

Efficacy News and Research

Thrombogenics issues business update and half year results

Milestone reached in Biotie Wyeth collaboration for the development of PDE10 inhibitors for schizophrenia

NAT gains importance as traditional testing methods become inadequate

Opinion piece outlines new model for foreign aid

Elorac offers Zithranol-RR for treating plaque psoriasis

Infectious Disease Research Institute commences clinical trial of its leishmaniasis vaccine in Sudan

NIMH grants Xhale $1.7 million to develop the SMART medication adherence system for HIV/AIDS therapies

Medical journal article highlights the challenges faced by healthcare providers for treating patients with non-healing wounds

E-18 files for an international patent for its revolutionary self-sheathing medical safety syringe technology

Sunquest Information Systems to co-develop laboratory information system with MGH, Partners HealthCare System

FDA approves clinical study of ATS 3f(R) Aortic Bioprosthesis with the younger aortic valve replacement population

Clinical data added to ORENCIA labeling help treat patients with rheumatoid arthritis

Stemedica unveils two of its latest scientific discoveries at the 2009 World Stem Cell Summit

BMSN and ENTB collaborate with Therinjectto to develop a new immuno-therapeutic cancer vaccine

QRxPharma completes its pilot evaluation study investigating the efficacy of MoxDuo capsules

Study reveals effectiveness of BioElectronics' ActiPatch therapy device for treating heel and foot pain

Link between collagen deficiency and osteoarthritis found in mice

FDA releases consumer health information updates

Collagen deficiency in mice causes premature development of osteoarthritis and degenerative disc disease

BioAlliance Pharma's LIP phase III pivotal study provides positive preliminary results

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News